Breast最新文献

{"title":"Real-world comparative effectiveness of first-line abemaciclib versus palbociclib in HR+/HER2- metastatic breast cancer: A propensity-matched retrospective analysis.","authors":"Cho-Hao Lee, Po-Huang Chen, Hong-Jie Jhou, Wei-Cheng Chang, Hsin-Yu Chen, Li-Ting Kao, Tina Yi-Jin Hsieh, Ming-Shen Dai","doi":"10.1016/j.breast.2025.104597","DOIUrl":"https://doi.org/10.1016/j.breast.2025.104597","url":null,"abstract":"<p><strong>Background: </strong>In the first-line treatment of hormone receptor-positive, HER2-negative (HR+/HER2-) metastatic breast cancer (mBC), the comparative effectiveness of different cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) remains unclear due to the absence of head-to-head randomized trials. We aimed to compare the real-world outcomes of abemaciclib versus palbociclib.</p><p><strong>Methods: </strong>We performed a retrospective, propensity-matched cohort study using the TriNetX Analytics Network database (2014-2025). The primary outcome was overall survival (OS). To ensure robust findings, the analysis was supported by multiple sensitivity tests, including restricted mean survival time (RMST) to provide a model-free effect measure, and E-value analysis to quantify the potential impact of unmeasured confounding.</p><p><strong>Results: </strong>From 15,830 eligible patients, we created a matched cohort of 2768 patients on abemaciclib and 2768 on palbociclib. After a median follow-up of 33.7 months for the abemaciclib group and 44.2 months for the palbociclib group, treatment with abemaciclib was associated with significantly longer median OS (6.0 vs. 5.0 years; HR 0.80, 95 % CI 0.72-0.90; p < 0.001). The RMST analysis confirmed a significant survival benefit of 5.96 months over the follow-up period (p < 0.001). Abemaciclib was associated with lower rates of neutropenia but higher rates of diarrhea. The survival advantage was consistent across sensitivity and subgroup analyses.</p><p><strong>Conclusions: </strong>In this large, real-world cohort study, first-line abemaciclib was associated with a significant overall survival benefit compared to palbociclib for patients with HR+/HER2-mBC. This finding was robust across multiple sensitivity analyses. These results provide valuable evidence to inform treatment decisions in the absence of direct randomized trial data.</p>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"84 ","pages":"104597"},"PeriodicalIF":7.9,"publicationDate":"2025-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145298372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Best practices for communication of prognosis and end-of-life discussions with patients with advanced breast cancer: A report from the advanced breast cancer global alliance.","authors":"Lesley Fallowfield, Belinda E Kiely, Luzia Travado, Roberta Ventura, Jessica Dullehan, Fatima Cardoso","doi":"10.1016/j.breast.2025.104595","DOIUrl":"https://doi.org/10.1016/j.breast.2025.104595","url":null,"abstract":"<p><strong>Purpose: </strong>Navigating prognosis and end-of-life (EoL) communications in advanced breast cancer (ABC) is difficult for healthcare professionals, people with the disease, and their caregivers. Greater multidisciplinary guidance is needed to optimise the effectiveness of these discussions.</p><p><strong>Methods: </strong>In November 2023, the ABC Global Alliance held a multidisciplinary workshop at their annual meeting in Lisbon, Portugal, exploring practices in communicating prognosis and discussing EoL with people with ABC. Seventy-one participants from 27 countries participated in the workshop. Reference and insights from secondary research were reviewed and incorporated into the workshop findings.</p><p><strong>Results: </strong>Workshop participants proposed a number of best practices for communicating prognosis and discussing EoL with people living with ABC, which aligned with four key topics: (1) When EoL discussions should happen - although individual preferences might differ, most participants felt this should be when life expectancy was within 6-12 months. (2) Who should be involved - if acceptable to the patient, presence of a care-giver or other family member should be encouraged. (3) What should be discussed- there was broad agreement for honesty with a realistic approximation of prognosis providing best and worst case scenarios all the time helping patients to maintain hope for plausible outcomes. (4) How EoL such conversations should be conducted- these sensitive conversations need to be conducted preferably by a Multidisciplinary Team Member (MDT) member who knows the patient and is trusted by them. Provision of a safe environment and plenty of time for discussion were seen as pre-requisites.</p><p><strong>Conclusion: </strong>The workshop highlighted the complexity of EoL communication in ABC. Participants identified challenges and opportunities, and suggested best practices. While these approaches should be universally adopted, they must always be guided by patient preferences, considering individual and cultural differences to ensure compassionate and effective communication.</p>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"84 ","pages":"104595"},"PeriodicalIF":7.9,"publicationDate":"2025-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145298371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overdiagnosis of ductal carcinoma in situ by grade and definition in population-based screening: A modeling study.","authors":"Keris Poelhekken, Marcel J W Greuter, Bert van der Vegt, Monique D Dorrius, Geertruida H de Bock","doi":"10.1016/j.breast.2025.104594","DOIUrl":"https://doi.org/10.1016/j.breast.2025.104594","url":null,"abstract":"<p><strong>Aim: </strong>To estimate ductal carcinoma in situ (DCIS) overdiagnosis overall and by grade in population-based screening and to determine the variation in overdiagnosis estimates by definition.</p><p><strong>Methods: </strong>Using a fully validated micro-simulation Markov model for DCIS (SimDCIS), the number, rate, and proportion of DCIS overdiagnoses were estimated overall and by grade. Overdiagnoses comprised excess DCIS cases in the screened versus the unscreened population; overdiagnosis rate equaled the number of DCIS overdiagnoses per 100,000 screened women; and DCIS overdiagnosis proportion equaled overdiagnosed DCIS divided by total diagnosed DCIS in the screened population. Base estimates for overdiagnosed DCIS were from a population perspective (ages 50-100 years) and included screen-detected, clinically detected, or progressed DCIS (i.e., invasive breast cancer with DCIS precursor). Overdiagnosis was also estimated for alternative definitions and perspectives. Univariate and probabilistic sensitivity analyses were performed to estimate uncertainty.</p><p><strong>Results: </strong>Base definitions yielded an overdiagnosis rate of 38.1 (range, 25.7-58.7) per 100,000 screened women and a proportion of 20 % (range 13 %-30 %). Stratification by grade showed 24 %, 20 %, and 18 % proportion overdiagnosis for grades 1, 2, and 3, respectively. Varying the definition led to overdiagnosis estimates from 18 % to 94 %; these overdiagnosis estimates increased by 36 %-49 % when excluding invasive breast cancer and by 54 %-71 % when including only screen-detected DCIS. Individual perspective estimates were 12 % higher than population perspective estimates.</p><p><strong>Conclusion: </strong>In biennial screening, approximately 1 in 5 DCIS is overdiagnosed, but with minimal variation between grades. A consensus definition and perspective for overdiagnosis would reduce the observed variation in DCIS overdiagnosis estimates.</p>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"84 ","pages":"104594"},"PeriodicalIF":7.9,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145285607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Addressing health literacy gaps in adjuvant endocrine therapy adherence: Post hoc insights from a randomized remote monitoring trial.","authors":"Ilana Graetz, Samuel Hernandez, Xin Hu, Rebecca A Krukowski, Janeane N Anderson, Teresa M Waters, Edward Stepanski, Gregory A Vidal, Lee S Schwartzberg","doi":"10.1016/j.breast.2025.104552","DOIUrl":"10.1016/j.breast.2025.104552","url":null,"abstract":"<p><p>Adjuvant endocrine therapy (AET) improves survival in hormone receptor-positive breast cancer, yet adherence is often lower among individuals with limited health literacy. This post hoc analysis of the THRIVE trial examined whether health literacy modified the effectiveness of two remote monitoring interventions (App-only and App + Feedback) versus enhanced usual care (EUC) on 12-month AET adherence (≥80 % of prescribed doses via connected pillbox). Among participants with lower health literacy, adherence was higher with App + Feedback than EUC (80.0 % vs. 42.1 %, p = 0.03), with no significant differences among those with higher health literacy. Tailored digital interventions may support adherence among patients with limited health literacy. TRIAL: ClinicalTrial.gov identifier NCT03592771.</p>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"83 ","pages":"104552"},"PeriodicalIF":7.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12356040/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144803511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fertility and ovarian function preservation in young women with breast cancer: A joint analysis of the Joven & Fuerte and PREFER prospective studies.","authors":"Fernanda Mesa-Chavez, Maria Grazia Razeti, Eva Blondeaux, Alejandra Platas, Virginia Delucchi, Alan Fonseca, Valeria Fontana, Marlid Cruz-Ramos, Paola Anserini, Manuel Rolando Gracía Garza, Edoardo Chiappe, Alejandro Mohar, Laura Orlando, Paula Cabrera-Galeana, Saverio Cinieri, Enrique Bargallo-Rocha, Lucia Del Mastro, Cynthia Villarreal-Garza, Matteo Lambertini","doi":"10.1016/j.breast.2025.104592","DOIUrl":"https://doi.org/10.1016/j.breast.2025.104592","url":null,"abstract":"<p><strong>Background: </strong>Potential infertility and premature ovarian insufficiency represent notable concerns for young women with breast cancer (YWBC) undergoing chemotherapy. Cryopreservation techniques and temporary ovarian suppression with GnRH agonists (GnRHa) can be offered for fertility preservation (FP) and/or ovarian protection. This joint analysis of the Joven & Fuerte and PREFER multicenter prospective studies compared the uptake of these strategies and associated factors among Mexican and Italian YWBC.</p><p><strong>Methods: </strong>Females ≤40 years diagnosed with non-metastatic BC from 2014 to 2019, who were offered FP strategies before (neo)adjuvant chemotherapy were included. Uptake of GnRHa for ovarian protection and cryopreservation procedures and reasons for their non-utilization were examined.</p><p><strong>Results: </strong>Among 485 patients (74 % from Mexico; 26 % from Italy), cryopreservation techniques were used in 8 % of Mexican patients and 25 % of Italian patients (p < 0.001). Methods in Mexico and Italy, respectively, comprised oocyte (50 % and 87 %), embryo (53 % and 0 %), and ovarian tissue (0 % and 16 %) cryopreservation. GnRHa were used in 98 % of Italian patients and 6 % of Mexican patients. Cryopreservation uptake was associated with younger age (OR 1.2, 95 %CI 1.1-1.2), childlessness (OR 21.8, 95 %CI 10.0-47.6), stage I-II BC (OR 3.1, 95 %CI 1.5-6.3), private healthcare in Mexico (OR 3.0, 95 %CI 1.1-8.1), and unpartnered status in Italy (OR 5.4, 95 %CI 2.2-13.2).</p><p><strong>Conclusion: </strong>FP and ovarian protection uptake were markedly higher in Italy than Mexico, possibly reflecting divergent social and healthcare contexts, though cryopreservation remained underutilized in both countries. Improved access to oncofertility services is warranted to provide comprehensive care aligned with the personal needs and life plans of YWBC.</p>","PeriodicalId":9093,"journal":{"name":"Breast","volume":" ","pages":"104592"},"PeriodicalIF":7.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145257408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term survival outcomes of male breast cancer: the propensity score matching analysis of nationwide registry database.","authors":"Nayeon Choi, Sohyun Moon, Jin Sung Kim, Ah Yoon Kim, Jee Hyun Ahn, Yireh Han, Joohyun Woo, Hyunjik Kim, Min Sung Chung, Chihwan David Cha","doi":"10.1016/j.breast.2025.104556","DOIUrl":"10.1016/j.breast.2025.104556","url":null,"abstract":"<p><strong>Background: </strong>s: Few studies have examined the prognosis of male breast cancer patients in Western countries. However, data on the long-term outcomes in Asian male patients are limited. Thus, we aimed to compare long-term survival outcomes between male and female patients including cancer-specific mortality.</p><p><strong>Methods: </strong>We included male patients diagnosed with primary breast cancer between 1981 and 2014 using nationwide data from the Korean Breast Cancer Registry (KBCR). After propensity score matching with female patients using covariates such as age, year of diagnosis, stage, and hormone receptor status, survival analyses using the Kaplan-Meier method and log-rank test were performed to evaluate breast cancer-specific survival (BCSS) and overall survival (OS).</p><p><strong>Results: </strong>After matching 680 patients, the median age was 62 years for male patients. Most patients underwent mastectomy, and 35.3 % had stage 1 disease. Ten years after diagnosis, there was no significant difference in the BCSS rates between the sexes. However, the OS rate was lower in males that in females (68.0 % vs. 79.0 %, p = 0.027). There was no significant improvement in survival outcomes among male patients in the late diagnostic period (2000-2010) compared to those in the early period (1981-1999).</p><p><strong>Conclusion: </strong>In this nationwide cohort study, we observed no improvement in survival outcomes among male breast cancer patients diagnosed in the recent years. Despite similar BCSS between sexes, male patients demonstrated significantly worse OS than female patients, likely due to higher non-cancer-related mortality.</p>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"83 ","pages":"104556"},"PeriodicalIF":7.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12356450/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144811722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Opportunities to improve the environmental sustainability of breast cancer care: A scoping review","authors":"Amanda Mac ,&nbsp;Adam Fontebasso ,&nbsp;Christine Lam ,&nbsp;Janet Tang ,&nbsp;Ela Howard ,&nbsp;Emma Reel ,&nbsp;Marina Englesakis ,&nbsp;Tulin D. Cil","doi":"10.1016/j.breast.2025.104593","DOIUrl":"10.1016/j.breast.2025.104593","url":null,"abstract":"<div><h3>Background</h3><div>Breast cancer is the most common cancer affecting women and is second in female cancer-related mortality. The treatment of breast cancer is multidisciplinary; it involves multiple specialists and allied health professionals and thus can be resource intensive. The environmental impact of breast cancer care has been poorly defined. The aim of this scoping review was to characterize the environmental effects of multidisciplinary breast cancer care.</div></div><div><h3>Methods</h3><div>MEDLINE, MEDLINE In-Process/ePubs, Embase, Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews were searched using terms related to breast cancer and environmental impact. The search strategy was run from inception to October 11, 2023, and updated on July 17, 2025. Peer-reviewed records that discussed the environmental impact of breast cancer care practices were included.</div></div><div><h3>Results</h3><div>The search identified 6772 articles from which 36 were included for review. We synthesized the literature discussing environmental effects of all aspects of breast cancer care, including screening, diagnosis, surgery, radiation, and systemic therapies. Key findings include the use of mobile breast screening clinics to reduce carbon footprint associated with travel, strategies for optimizing resource consumption in the operating room, and environmentally sustainable approaches for radiotherapy and breast cancer drug administration.</div></div><div><h3>Conclusion</h3><div>This review summarizes the current literature discussing the environmental impact of breast cancer care. Findings from this review will identify gaps and inform recommendations for transforming our health care system into one that is sustainable and capable of offering gold standard patient-centred care to future generations of patients with breast cancer.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"84 ","pages":"Article 104593"},"PeriodicalIF":7.9,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145249664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing treatment gaps in breast cancer and intellectual disabilities","authors":"Parth Aphale,&nbsp;Shashank Dokania,&nbsp;Himanshu Shekhar","doi":"10.1016/j.breast.2025.104590","DOIUrl":"10.1016/j.breast.2025.104590","url":null,"abstract":"","PeriodicalId":9093,"journal":{"name":"Breast","volume":"84 ","pages":"Article 104590"},"PeriodicalIF":7.9,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145231510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond the first cut: Impact of repeat surgery versus boost on breast induration-A post hoc analysis from the DBCG HYPO & PBI trials","authors":"Kristine Wiborg Høgsbjerg ,&nbsp;Else Maae ,&nbsp;Mette Holck Nielsen ,&nbsp;Marie Louise Holm Milo ,&nbsp;Maja Vestmø Maraldo ,&nbsp;Peer Michael Christiansen ,&nbsp;Mette Skovhus Thomsen ,&nbsp;Jens Overgaard ,&nbsp;Birgitte Vrou Offersen ,&nbsp;the Danish Breast Cancer Group Radiotherapy Committee","doi":"10.1016/j.breast.2025.104587","DOIUrl":"10.1016/j.breast.2025.104587","url":null,"abstract":"<div><h3>Purpose</h3><div>Following breast-conserving surgery (BCS), patients with narrow surgical margins frequently undergo repeat surgery (RS) or receive a tumour-bed boost to reduce the risk of local recurrence. Both interventions may increase the risk of late toxicity, including breast induration and adverse cosmetic outcomes. Comparative long-term data on these outcomes remain limited. This post hoc analysis assessed the impact of RS and tumour-bed boost on grade 2–3 breast induration and cosmetic outcomes in patients receiving whole-breast irradiation (WBI) for early-stage breast cancer or ductal carcinoma in situ (DCIS).</div></div><div><h3>Results</h3><div>The analysis included 1919 patients from two multicentre randomised phase III trials within the Danish Breast Cancer Group (DBCG): DBCG HYPO (WBI 50Gy/25fr versus 40Gy/15fr) and DBCG PBI (40Gy/15fr, WBI versus partial breast irradiation (PBI)). Of these, 303 patients (16 %) underwent RS and 220 patients (11 %) received a boost. Patients were categorised into four groups: ‘RS and boost’, ‘boost only’, ‘RS only’, and ‘No RS, no boost’. At 5 years, the cumulative incidence of grade 2–3 breast induration was highest in the ‘RS and boost’ group (30.7 %), followed by ‘boost only’ (25.7 %), ‘RS only’ (18.1 %), and ‘No RS, no boost’ (13.5 %). Adjusted hazard ratios confirmed this pattern. No significant differences in cosmetic outcomes were observed between the ‘RS only’ and ‘boost only’ groups at 3 or 5 years.</div></div><div><h3>Conclusions</h3><div>A tumour-bed boost was associated with a higher risk of breast induration compared to RS, with no difference in cosmetic outcome.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"84 ","pages":"Article 104587"},"PeriodicalIF":7.9,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145217652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hypothyroidism is associated with radiation-induced pulmonary fibrosis.","authors":"Jinqiang You, Lian Li, Hongjuan Yang, Yuying Zhu, Xin Huang, Meng Li, Zhiyong Yuan, Wen Ning, Zhongjie Chen","doi":"10.1016/j.breast.2025.104591","DOIUrl":"https://doi.org/10.1016/j.breast.2025.104591","url":null,"abstract":"<p><strong>Introduction: </strong>Radiation-induced pulmonary fibrosis (RIPF) is a common late complication for breast cancer patients after radiation therapy (RT). Breast cancer patients are often accompanied by hypothyroidism. We therefore sought to evaluate the association between hypothyroidism and RIPF susceptibility.</p><p><strong>Materials and methods: </strong>We retrospectively analyzed 781 breast cancer patients who underwent postoperative intensity-modulated radiation therapy (IMRT) between 2020 and 2021. Univariate and multivariate Cox regression analyses were used to evaluate the prevalence of hypothyroidism between patients with or without RIPF. Propensity score matching (PSM) was employed to balance baseline characteristics between the two groups. Analysis of the occurrence time of RIPF was performed using the Kaplan-Meier Survival estimator.</p><p><strong>Results: </strong>Hypothyroidism was found to be significantly associated with RIPF susceptibility using univariate analysis (OR = 5.51; 95 % CI: 2.55-11.90; P = 0.001). When considering age, body mass index (BMI), diabetes, smoking, and surgical modality, multivariate analysis further confirmed the significant association of hypothyroidism with RIPF susceptibility (OR = 5.85; 95 % CI: 2.58-13.26; P = 0.001). Even after PSM, hypothyroidism remained significantly associated with RIPF susceptibility using both univariate (OR = 65.29; 95 % CI: 1.95-2181.19; P = 0.02) and multivariate analyses (OR = 6.03; 95 % CI: 2.69-13.50; P = 0.001), respectively. The occurrence time of RIPF was comparable between patients with or without hypothyroidism analyzed by data after PSM (Median occurrence time = 6 months in both groups, P = 0.055).</p><p><strong>Conclusions: </strong>Hypothyroidism is significantly associated with RIPF susceptibility in breast cancer patients treated with postoperative IMRT. These results highlight the potential of thyroid function as a modifiable risk factor in RIPF and underscore the need for further mechanistic and interventional studies.</p>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"84 ","pages":"104591"},"PeriodicalIF":7.9,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145291056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}